Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.56 |
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | GIPR | P48546 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | CALCR | P30988 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30933098 | 0.93 | REN (0.53) | OPRD1F2OPRM1OPRK1KEAP1 | |
| SCHEMBL30933101 | 0.91 | REN (0.54) | OPRD1F2OPRM1OPRK1 | |
| SCHEMBL22380731 | 0.90 | KDM1A (0.53) | OPRD1F2KEAP1 | |
| SCHEMBL22018606 | 0.89 | OPRD1 (0.48) | OPRD1F2OPRM1OPRK1KEAP1 | |
| SCHEMBL30933102 | 0.89 | NMUR2 (0.53) | OPRD1F2OPRM1OPRK1KEAP1 | |
| SCHEMBL29308367 | 0.87 | BCL2L1 (0.48) | OPRD1GLP1RGIPRF2OPRM1 | |
| SCHEMBL30933097 | 0.87 | APLNR (0.51) | OPRD1GLP1RGCGRGIPRF2 | |
| SCHEMBL29421924 | 0.87 | APLNR (0.49) | OPRD1GLP1RGCGRGIPROPRM1 | |
| SCHEMBL31191391 | 0.87 | OPRD1 (0.53) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30933107 | 0.86 | APLNR (0.51) | OPRD1GLP1RGCGRGIPROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020099925-A2 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2020-05-22 | — | — | WO | disclosed |